Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Gastrointestinal 3Genitourinary 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 1Neoplasm Metastasis 1Carcinoma, Islet Cell 1Carcinoma 1Carcinoid Tumor 1

Interventions

Everolimus 18lutetium Lu 177 dotatate 9lanreotide 8surufatinib 7Octreotide 7pasireotide 5amino-acid, glucose, and electrolyte solution 5Sunitinib 5Temozolomide 4Data Collection 4pembrolizumab 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2fosbretabulin 2arginyllysine 2anlotinib 2Paclitaxel 2PM 01183 2Lutetium-177 2Lutetium 2Irinotecan 2Injections 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × cixutumumab × NET × Clear all
NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡